CRSPHealthcare · BiotechnologyThe 22 Wall Street analysts covering CRISPR Therapeutics AG hold a median 12-month price target of $80 — +55.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 14 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores CRISPR Therapeutics AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (79): Analysts have, on balance, been raising their forecasts.
Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CRSP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +55.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Aug 2026 | Citizens | Reiterates | Market Outperform | $80 |
| 31 Aug 2026 | Needham | Reiterates | Buy | $82 |
| 25 Aug 2026 | Citizens | Reiterates | Market Outperform | $80 |
| 4 Aug 2026 | Citigroup | Maintains | Buy | $82 → $88 |
| 4 Aug 2026 | Citigroup | Maintains | Buy | — |
| 8 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $80 |
| 8 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 July 2026 | Citizens | Reiterates | Market Outperform | $80 |
| 6 July 2026 | Citizens | Reiterates | Market Outperform | — |
| 13 May 2026 | Bernstein | Maintains | Market Perform | — |
| 6 May 2026 | Citigroup | Maintains | Buy | — |
| 17 Mar 2026 | Piper Sandler | Reiterates | Overweight | — |
| 17 Feb 2026 | Chardan Capital | Maintains | Buy | — |
| 13 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 13 Feb 2026 | Needham | Maintains | Buy | — |
| 13 Feb 2026 | TD Cowen | Maintains | Hold | — |
| 30 Jan 2026 | Citizens | Maintains | Market Outperform | — |
| 23 Dec 2025 | Citizens | Reiterates | Market Outperform | — |
| 23 Dec 2025 | Needham | Reiterates | Buy | — |
| 26 Nov 2025 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRSP appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Oct 2026, CRISPR Therapeutics AG returned −28.3% against +16.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 2% of US stocks
Cheaper than 33% of US stocks
Cheaper than 82% of US stocks
Higher than 99% of US stocks
Higher than 1% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 29% of US stocks
Higher than 23% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CRISPR Therapeutics AG has a market value of $4.8B and an enterprise value of $3.4B.
Revenue in the twelve months to 30 June 2026: $11.0M. The latest quarter grew 1041.4% year on year.
Net income over the same four quarters: −$451.1M, a −4101.3% net margin.
Diluted earnings per share, trailing twelve months: $−4.76.
Free cash flow in the twelve months to 30 June 2026: −$373.8M.
Trailing P/E: −7.7×; forward P/E: −14.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CRISPR Therapeutics AG employs 393 people — $28K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CRISPR Therapeutics AG — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, down 3.45% from the prior day. The headline says the stock dipped more than the broader market.
Why it matters — The session's decline and its comparison with the broader market are relevant to investors tracking CRSP's recent trading performance.
Zacks reports that users of Zacks.com have recently been watching CRISPR Therapeutics (CRSP) closely. The item says it is worth knowing the facts that could shape the stock’s prospects.
Why it matters — The article draws attention to factors that may influence CRSP’s prospects, relevant to investors following the stock.
The Motley Fool reports that substantial revenue from Casgevy may be approaching and that investors can expect a pivotal update on CTX310 before year-end. The headline cites Citi's view of 60% upside, while noting that this depends on what has to go right.
Why it matters — Casgevy revenue and the anticipated CTX310 update are developments CRSP watchers may follow.
CRISPR Therapeutics announced that clinical data from the Phase 1b trial of CTX310, its investigational in vivo gene-editing therapy targeting ANGPTL3 in patients with severe hypertriglyceridemia, will be presented as a late-breaking oral presentation at the AHA Scientific Sessions 2026 on November 9.
Why it matters — The presentation will provide a scheduled forum for sharing clinical data on CRSP’s CTX310 program.
CRISPR Therapeutics AG (CRSP) settled at $54 on the latest trading day, down 5.82% from its previous close.
Why it matters — The report gives CRSP watchers a snapshot of the stock’s latest daily move.
The 22 Wall Street analysts covering CRISPR Therapeutics AG have a median 12-month price target of $80, with estimates ranging from $44 to $291. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 22 analysts covering CRISPR Therapeutics AG, 13 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CRISPR Therapeutics AG 41 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, CRISPR Therapeutics AG ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (79 of 100).
No one can know that. What the data says: the median 12-month target from 22 analysts implies +55.3% from the last close, and Ticker Nerd's factor model ranks CRISPR Therapeutics AG 41 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CRISPR Therapeutics AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $291 over the next 12 months.
CRISPR Therapeutics AG returned -28.3% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing and the development of CRISPR/Cas9-based medicines for serious human diseases. Its research and therapeutic portfolio spans areas such as hemoglobinopathies, oncology, regenerative medicine, autoimmune disorders, and type 1 diabetes.
The most recent item we track (Zacks Investment Research, 12 Oct 2026): "CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know". CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, down 3.45% from the prior day. The headline says the stock dipped more than the broader market.
CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing and the development of CRISPR/Cas9-based medicines for serious human diseases. Its research and therapeutic portfolio spans areas such as hemoglobinopathies, oncology, regenerative medicine, autoimmune disorders, and type 1 diabetes. The company’s work centers on using precise genome editing to create targeted cell and gene therapies, with a particular emphasis on advancing treatments derived from its proprietary CRISPR platform. CRISPR Therapeutics AG also collaborates with partners in the life sciences sector to develop and commercialize selected programs, strengthening its role in the broader healthcare innovation landscape. Headquartered in Zug, Switzerland, the company is a notable participant in the biotechnology market, where it contributes to the growing field of gene-based medicine.
CEO Dr. Samarth Kulkarni Ph.D. · 393 employees · Switzerland · https://www.crisprtx.com
